Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited (ASX:IMU) for $6 million on April 16, 2024. Imugene will also transfer process and analytical development of Azer-cel to Kincell in order to support process and method optimization for commercial readiness.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.082 AUD | +3.80% | +15.49% | -25.45% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.45% | 377M | |
+2.23% | 42.75B | |
+47.70% | 41.61B | |
+11.89% | 41.34B | |
-8.83% | 26.59B | |
+6.52% | 25.49B | |
-22.97% | 18.12B | |
+30.28% | 12.24B | |
-2.23% | 11.76B | |
+9.22% | 11B |
- Stock Market
- Equities
- IMU Stock
- News Imugene Limited
- Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.